Xencor Shares Signal Potential Biotech Revival

Biotechnology firm Xencor has given investors substantial reasons for optimism following a prolonged downturn. The company’s latest quarterly report revealed dramatically improved operational metrics and significant clinical development progress, raising questions about whether this marks the beginning of a sustainable recovery.

Xencor’s financial position strengthened considerably according to third-quarter 2025 results released November 5. The company slashed its net loss by an impressive 87%, dropping from $46.3 million during the same period last year to just $6.0 million. Revenue performance also showed positive momentum, climbing 18% to reach $21.0 million, primarily driven by licensing payments from partners including Alexion and Incyte.

The company maintains a robust liquidity position with approximately $634 million in cash and Read more...